Adverse effects of hormones and hormone antagonists on the liver

Drug-Induced Liver Disease

Volumn , Issue , 2013, Pages 605-619

  Chitturi, Shivakumar ^a   Farrell, Geoffrey C ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Anabolic steroids; Antithyroid drugs; Cholestasis; Oral contraceptives; Tamoxifen

Indexed keywords

EID: 84882580188     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387817-5.00033-9     Document Type: Chapter

References (160)

1. Elouni B., Ben Salem C., Zamy M., Ganne N., Beaugrand M., Bouraoui K., et al. Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports. Ann Pharmacother 2010, 44:2035-2037.
2. Bennion L.J., Ginsberg R.L., Gernick M.B., Bennett P.H. Effects of oral contraceptives on the gallbladder bile of normal women. N Engl J Med 1976, 294:189-192.
3. Lindberg M.C. Hepatobiliary complications of oral contraceptives. J Gen Intern 1992, 7:199-209.
4. Kern F., Everson G.T., DeMark B., McKinley C., Showalter R., Erfling W., et al. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J Clin Invest 1981, 68:1229-1242.
5. Rooks J.B., Ory H.W., Ishak K.G., Strauss L.T., Greenspan J.R., Hill A.P., et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979, 242:644-648.
6. Haemmerli U.P., Wyss H.I. Recurrent intrahepatic cholestasis of pregnancy. Report of six cases, and review of the literature. Medicine (Baltimore) 1967, 46:299-321.
7. Holzbach R.T., Sivak D.A., Braun W.E. Familial recurrent intrahepatic cholestasis of pregnancy: a genetic study providing evidence for transmission of a sex-limited, dominant trait. Gastroenterology 1983, 85:175-179.
8. Stieger B., Fattinger K., Madon J., Kullak-Ublick G.A., Meier P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000, 118:422-430.
9. Pasmant E., Goussard P., Baranes L., Laurendeau I., Quentin S., Ponsot P., et al. First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptive-induced cholestasis. Eur J Hum Genet 2012 Mar, 20(3):277-282.
10. Meier Y., Zodan T., Lang C., Zimmermann R., Kullak-Ublick G.A., Meier P.J., et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008, 14:38-45.
11. Marinelli R.A., Lehmann G.L., Soria L.R., Marchissio M.J. Hepatocyte aquaporins in bile formation and cholestasis. Front Biosci 2011, 17:2642-2652.
12. Anand V., Gorard D.A. Norethisterone-induced cholestasis. QJM 2005, 98:232-234.
13. Foitl D.R., Hyman G., Lefkowitch J.H. Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer. Cancer 1989, 63:438-439.
14. Schaffner F The effect of oral contraceptives on the liver. JAMA 1966, 198:1019-1021.
15. Chitturi S., Farrell G.C. Drug-induced cholestasis. Semin Gastrointest Dis 2001, 12:113-124.
16. Farrell G.C. Drug-induced cholestasis. Drug-induced liver disease 1994, 331. Churchill Livingstone, London, [Chap. 14]. G.C. Farrell (Ed.).
17. Schonberg L.A. Peliosis hepatis and oral contraceptives. A case report. J Reprod Med 1982, 27:753-756.
18. Staub P.G., Leibowitz C.B. Peliosis hepatis associated with oral contraceptive use. Australas Radiol 1996, 40:172-174.
19. Corpa M.V., Bacchi M.M., Bacchi C.E., Coelho K.I. Peliosis hepatis associated with lymphoplasmacytic lymphoma: an autopsy case report. Arch Pathol Lab Med 2004, 128:1283-1285.
20. Gushiken F.C. Peliosis hepatis after treatment with 2-chloro-3′-deoxyadenosine. South Med J 2000, 93:625-626.
21. Janssen H.L., Meinardi J.R., Vleggaar F.P., van Uum S.H., Haagsma E.B., van Der Meer F.J., et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000, 96:2364-2368.
22. Valla D., Le M.G., Poynard T., Zucman N., Rueff B., Benhamou J.P. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986, 90:807-811.
23. Gomes M.P., Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004, 164:1965-1976.
24. Chu G., Farrell G.C. Portal vein thrombosis associated with prolonged ingestion of oral contraceptive steroids. J Gastroenterol Hepatol 1993, 8:390-393.
25. Maddrey W.C. Hepatic vein thrombosis (Budd Chiari syndrome): possible association with the use of oral contraceptives. Semin Liver Dis 1987, 7:32-39.
26. Minnema M.C., Janssen H.L., Niermeijer P., de Man R.A. Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. J Hepatol 2000, 33:509-512.
27. Gemer O., Moscovici O., Ben-Horin C.L., Linov L., Peled R., Segal S. Oral contraceptives and liver hemangioma: a case-control study. Acta Obstet Gynecol Scand 2004, 83:1199-1201.
28. Saegusa T., Ito K., Oba N., Matsuda M., Kojima K., Tohyama K., et al. Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy. Intern Med 1995, 34:207-211.
29. Conter R.L., Longmire W.P. Recurrent hepatic hemangiomas. Possible association with estrogen therapy. Ann Surg 1988, 207:115-119.
30. Xiao X., Hong L., Sheng M. Promoting effect of estrogen on the proliferation of hemangioma vascular endothelial cells in vitro. J Pediatr Surg 1999, 34:1603-1605.
31. Reddy K.R., Kligerman S., Levi J., Livingstone A., Molina E., Franceschi D., et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001, 67:173-178.
32. Mathieu D., Kobeiter H., Maison P., Rahmouni A., Cherqui D., Zafrani E.S., et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000, 118:560-564.
33. Scalori A., Tavani A., Gallus S., La Vecchia C., Colombo M. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002, 186:195-197.
34. Baum J.K., Bookstein J.J., Holtz F., Klein E.W. Possible association between benign hepatomas and oral contraceptives. Lancet 1973, 2:926-929.
35. Edmondson HA. Tumors of the liver and intrahepatic bile ducts. In: Atlas of tumor pathology. Section 7, Fascicle 25. AFIP, Washington, DC: 1958. p. 193-206.
36. Edmondson H.A., Henderson B., Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976, 294:470-472.
37. Blayney A.W., O'Callaghan T., MacErlean D.P., O'Connell T.C. Fatal outcome of an hepatic adenoma following short term oral contraceptive use. Ir Med J 1977, 70:455-456.
38. Kerlin P., Davis G.L., McGill D.B., Weiland L.H., Adson M.A., Sheedy P.F. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983, 84:994-1002.
39. Aseni P., Sansalone C.V., Sammartino C., Benedetto F.D., Carrafiello G., Giacomoni A., et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 2001, 33:234-236.
40. Yu M.C., Yuan J.M. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004, 127:S72-S78.
41. Henderson B.E., Preston-Martin S., Edmondson H.A., Peters R.L., Pike M.C. Hepatocellular carcinoma and oral contraceptives. Br J Cancer 1983, 48:437-440.
42. Neuberger J., Forman D., Doll R., Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed) 1986, 292:1355-1357.
43. Forman D., Vincent T.J., Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J (Clin Res Ed) 1986, 292:1357-1361.
44. Palmer J.R., Rosenberg L., Kaufman D.W., Warshauer M.E., Stolley P., Shapiro S. Oral contraceptive use and liver cancer. Am J Epidemiol 1989, 130:878-882.
45. Yu M.C., Tong M.J., Govindarajan S., Henderson B.E. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991, 83:1820-1826.
46. Hsing A.W., Hoover R.N., McLaughlin J.K., Co-Chien H.T., Wacholder S., Blot W.J., et al. Oral contraceptives and primary liver cancer among young women. Cancer Causes Control 1992, 3:43-48.
47. Tavani A., Negri E., Parazzini F., Franceschi S., La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993, 67:635-637.
48. The Collaborative MILTS Project Team Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 1997, 56:275-284.
49. Maheshwari S., Sarraj A., Kramer J., El-Serag H.B. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007, 47:506-513.
50. Hannaford P.C., Selvaraj S., Elliott A.M., Angus V., Iversen L., Lee A.J. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007, 335:651.
51. Ishak K.G., Zimmerman H.J. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 1987, 7:230-236.
52. Kew M.C., Song E., Mohammed A., Hodkinson J. Contraceptive steroids as a risk factor for hepatocellular carcinoma: a case/control study in South African black women. Hepatology 1990, 11:298-302.
53. Dourakis S.P., Tolis G. Sex hormonal preparations and the liver. Eur J Contracept Reprod Health Care 1998, 3:7-16.
54. Gelfand M.M., Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997, 19:383-404. [discussion 367-8].
55. Singhal S., Jain S., Singla M., Pippal R.B., Gondal R., Agarwal A., et al. Multifocal epithelioid hemangioendothelioma of liver after long-term oral contraceptive use-a case report and discussion of management difficulties encountered. J Gastrointest Cancer 2009, 40:59-63.
56. Makhlouf H.R., Ishak K.G., Goodman Z.D. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer 1999, 85:562-582.
57. Dean P.J., Haggitt R.C., O'Hara C.J. Malignant epithelioid hemangioendothelioma of the liver in young women. Relationship to oral contraceptive use. Am J Surg Pathol 1985, 9:695-704.
58. Shi E.C., Fischer A., Crouch R., Ham J.M. Possible association of angiosarcoma with oral contraceptive agents. Med J Aust 1981, 1:473-474.
59. Thung S.N., Gerber M.A. Precursor stage of hepatocellular neoplasm following long exposure to orally administered contraceptives. Hum Pathol 1981, 12:472-474.
60. Krishnan P.V., Feng Z.Z., Gordon S.C. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J Clin Gastroenterol 2009, 43:672-675.
61. Yoshida E.M., Erb S.R., Scudamore C.H., Owen D.A. Severe cholestasis and jaundice secondary to an esterified testosterone, a non-C17 alkylated anabolic steroid. J Clin Gastroenterol 1994, 18:268-270.
62. Glober G.A., Wilkerson J.A. Biliary cirrhosis following the administration of methyltestosterone. JAMA 1968, 204:170-173.
63. Farrell G.C Drug-induced liver disease. Current hepatology 1997, Vol. 17:131-168. Mosby-Year Book, St Louis.
64. Gurakar A., Caraceni P., Fagiuoli S., Van Thiel D.H. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J Okla State Med Assoc 1994, 87:399-404.
65. Stimac D., Milic S., Dintinjana R.D., Kovac D., Ristic S. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002, 35:350-352.
66. Bispo M., Valente A., Maldonado R., Palma R., Gloria H., Nobrega J., et al. Anabolic steroid-induced cardiomyopathy underlying acute liver failure in a young bodybuilder. World J Gastroenterol 2009, 15:2920-2922.
67. Schwingel P.A., Cotrim H.P., Salles B.R., Almeida C.E., dos Santos C.R., Nachef B., et al. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. Liver Int 2011, 31:348-353.
68. Zafrani E.S., von Pinaudeau Y., Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983, 143:495-502.
69. Choi S.K., Jin J.S., Cho S.G., Choi S.J., Kim C.S., Choe Y.M., et al. Spontaneous liver rupture in a patient with peliosis hepatis: a case report. World J Gastroenterol 2009, 15:5493-5497.
70. Johnson F.L., Lerner K.G., Siegel M., Feagler J.R., Majerus P.W., Hartmann J.R., et al. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972, 2:1273-1276.
71. Farrell G.C., Joshua D.E., Uren R.F., Baird P.J., Perkins K.W., Kronenberg H. Androgen-induced hepatoma. Lancet 1975, 1:430-432.
72. Velazquez I., Alter B.P. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004, 77:257-267.
73. Bork K., Pitton M., Harten P., Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999, 353:1066-1067.
74. Shahidi N.T. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001, 23:1355-1390.
75. McCaughan G.W., Bilous M.J., Gallagher N.D. Long-term survival with tumor regression in androgen-induced liver tumors. Cancer 1985, 56:2622-2626.
76. Anthony P.P. Letter: hepatoma associated with androgenic steroids. Lancet 1975, 1:685-686.
77. Falk H., Thomas L.B., Popper H., Ishak K.G. Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet 1979, 2:1120-1123.
78. Martin N.M., Abu Dayyeh B.K., Chung R.T. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol 2008, 14:4573-4575.
79. Guy J.T., Auslander M.O. Androgenic steroids and hepatocellular carcinoma. Lancet 1973, 1:148.
80. Saphner T., Triest-Robertson S., Li H., Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009, 115:3189-3195.
81. Bruno S., Maisonneuve P., Castellana P., Rotmensz N., Rossi S., Maggioni M., et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005, 330:932.
82. Elefsiniotis I.S., Pantazis K.D., Ilias A., Pallis L., Mariolis A., Glynou I., et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol 2004, 16:593-598.
83. Nishino M., Hayakawa K., Nakamura Y., Morimoto T., Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol 2003, 180:129-134.
84. Nguyen M.C., Stewart R.B., Banerji M.A., Gordon D.H., Kral J.G. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 2001, 25:296-298.
85. Cai Q., Bensen M., Greene R., Kirchner J. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 2000, 95:277-279.
86. Dray X., Tainturier M.H., De La Lande P., Marty O., Mallet L. Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen. Gastroenterol Clin Biol 2000, 24:1122-1123.
87. Oien K.A., Moffat D., Curry G.W., Dickson J., Habeshaw T., Mills P.R., et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999, 353:36-37.
88. Ogawa Y., Murata Y., Nishioka A., Inomata T., Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998, 351:725.
89. Pinto H.C., Baptista A., Camilo M.E., de Costa E.B., Valente A., de Moura M.C. Tamoxifen-associated steatohepatitis-report of three cases. J Hepatol 1995, 23:95-97.
90. Van Hoof M., Rahier J., Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 1996, 124:855-856.
91. Pratt D.S., Knox T.A., Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med 1995, 123:236.
92. Storen E.C., Hay J.E., Kaur J., Zahasky K., Hartmann L. Tamoxifen-induced submassive hepatic necrosis. Cancer J 2000, 6:58-60.
93. Ching C.K., Smith P.G., Long R.G. Tamoxifen-associated hepatocellular damage and agranulocytosis. Lancet 1992, 339:940.
94. Choi J.S., Kim M.J. Education and imaging: hepatobiliary and pancreatic: focal steatohepatitis mimicking a metastasis. J Gastroenterol Hepatol 2011, 26:415.
95. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
96. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis 2002, 22:185-194.
97. Larosche I., Letteron P.H., Mansouri A Tamoxifen inhibits mitochondrial function, topoisomerases and mitochondrial DNA synthesis, and causes progressive mitochondrial DNA depletion and steatosis in mouse liver. J Hepatol 2005, 42(Suppl. 2):23-24.
98. Fukumoto M., Masuda K., Ogawa Y., Nishioka A., Ohnishi T., Murata Y., et al. In vivo imaging of hepatic fatty acid metabolism in patients with nonalcoholic steatohepatitis using semiquantative (123)I-BMIPP liver scan. Hepatol Res 2005, 33:105-109.
99. Lelliott C.J., Lopez M., Curtis R.K., Parker N., Laudes M., Yeo G., et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J 2005, 19:1108-1119.
100. Cole L.K., Jacobs R.L., Vance D.E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 2010, 52:1258-1265.
101. Ohnishi T., Ogawa Y., Saibara T., Nishioka A., Kariya S., Fukumoto M., et al. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Oncol Rep 2005, 13:485-489.
102. Nemoto Y., Toda K., Ono M., Fujikawa-Adachi K., Saibara T., Onishi S., et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 2000, 105:1819-1825.
103. Lee M.H., Kim J.W., Kim J.H., Kang K.S., Kong G., Lee M.O. Gene expression profiling of murine hepatic steatosis induced by tamoxifen. Toxicol Lett 2010, 199:416-424.
104. Saibara T., Onishi S., Ogawa Y., Yoshida S., Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999, 353:1802.
105. Hamada N., Ogawa Y., Saibara T., Murata Y., Kariya S., Nishioka A., et al. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 2000, 17:1119-1123.
106. Olsson R., Tyllstrom J., Zettergren L. Hepatic reactions to cyclofenil. Gut 1983, 24:260-263.
107. Manso G., Thole Z., Salgueiro E., Revuelta P., Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 2006, 15:253-259.
108. Thole Z., Manso G., Salgueiro E., Revuelta P., Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004, 73:289-295.
109. Dawson L.A., Chow E., Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997, 49:283-284.
110. Chodak G.W. Bicalutamide-associated fulminant hepatic failure. Urology 1997, 50:1027.
111. Castro Beza I., Sanchez Ruiz J., Peracaula Espino F.J., Villanego Beltran M.I. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade. Clin Transl Oncol 2008, 10:591-592.
112. O'Bryant C.L., Flaig T.W., Utz K.J. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy 2008, 28:1071-1075.
113. Anon High dose cypropterone and hepatotoxicity. Aust Adv Drug Reactions Bull 2004, 23:3.
114. Ibanez L., Jaramillo A., Ferrer A., de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 2005, 20:1833-1836.
115. Brahm J., Brahm M., Segovia R., Latorre R., Zapata R., Poniachik J., et al. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 2011, 10:93-98.
116. Miquel M., Soler A., Vaque A., Ojanguren I., Costa J., Planas R. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int 2007, 27:1144-1147.
117. Wysowski D.K., Freiman J.P., Tourtelot J.B., Horton M.L. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993, 118:860-864.
118. Watanabe S., Yamasaki S., Tanae A., Hibi I., Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc committee on androcur users. Lancet 1994, 344:1567-1568.
119. Garty B.Z., Dinari G., Gellvan A., Kauli R. Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate. Eur J Pediatr 1999, 158:367-370.
120. Grasl-Kraupp B., Luebeck G., Wagner A., Low-Baselli A., de Gunst M., Waldhor T., et al. Quantitative analysis of tumor initiation in rat liver: role of cell replication and cell death (apoptosis). Carcinogenesis 2000, 21:1411-1421.
121. Fau D., Eugene D., Berson A., Letteron P., Fromenty B., Fisch C., et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994, 269:954-962.
122. Fau D., Berson A., Eugene D., Fromenty B., Fisch C., Pessayre D. Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther 1992, 263:69-77.
123. Berson A., Schmets L., Fisch C., Fau D., Wolf C., Fromenty B., et al. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J Pharmacol Exp Ther 1994, 270:167-176.
124. Higuchi S., Kobayashi M., Yano A., Tsuneyama K., Fukami T., Nakajima M., et al. Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. J Appl Toxicol 2012, 32(10):815-822.
125. Gomez J.L., Dupont A., Cusan L., Tremblay M., Suburu R., Lemay M., et al. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992, 92:465-470.
126. Friedman G., Lamoureux E., Sherker A.H. Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci 1999, 44:1362-1363.
127. Famularo G., De Simone C., Minisola G., Nicotra G.C. Flutamide-associated acute liver failure. Ann Ital Med Int 2003, 18:250-253.
128. Cicognani C., Malavolti M., Morselli-Labate A.M., Sama C., Barbara L. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci 1996, 41:2219-2221.
129. Kojima M., Kamoi K., Ukimura O., Fujito A., Nakao M., Tanaka S., et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study. Int J Urol 2002, 9:42-46.
130. Targher G., Bertolini L., Rodella S., Zoppini G., Zenari L., Falezza G. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006, 64:337-341.
131. Loraschi A., Banfi P., Mauri M., Sessa F., Bono G., Cosentino M. Hepatotoxicity after high-dose methylprednisolone for demyelinating disease. Clin Neuropharmacol 2010, 33:52-54.
132. Nagai T., Imamura M., Kamiya Y., Mori M. Graves' disease accompanied by anti-myeloperoxidase antibody-related nephropathy and autoimmune hepatitis. Intern Med 2004, 43:516-520.
133. Marino M., Morabito E., Altea M.A., Ambrogini E., Oliveri F., Brunetto M.R., et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 2005, 28:280-284.
134. Malik R., Hodgson H. The relationship between the thyroid gland and the liver. QJM 2002, 95:559-569.
135. Huang M.J., Li K.L., Wei J.S., Wu S.S., Fan K.D., Liaw Y.F. Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study. Am J Gastroenterol 1994, 89:1071-1076.
136. Fong T.L., McHutchison J.G., Reynolds T.B. Hyperthyroidism and hepatic dysfunction. A case series analysis. J Clin Gastroenterol 1992, 14:240-244.
137. Hasan M.K., Tierney W.M., Baker M.Z. Severe cholestatic jaundice in hyperthyroidism after treatment with 131-iodine. Am J Med Sci 2004, 328:348-350.
138. Vitug A.C., Goldman J.M. Hepatotoxicity from antithyroid drugs. Horm Res 1985, 21:229-234.
139. Epeirier J.M., Pageaux G.P., Coste V., Perrigault P.F., Banc P., Larrey D., et al. Fulminant hepatitis after carbimazole and propranolol administration. Eur J Gastroenterol Hepatol 1996, 8:287-288.
140. Schwab G.P., Wetscher G.J., Vogl W., Redmond E. Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chir 1996, 381:225-227.
141. Lunzer M., Huang S.N., Ginsburg J., Ahmed M., Sherlock S. Jaundice due to carbimazole. Gut 1975, 16:913-917.
142. Binder C., Lang W. Necrotizing hepatitis with a fatal outcome after carbimazole therapy. Dtsch Med Wochenschr 1993, 118:1515-1519.
143. Kang H., Choi J.D., Jung I.G., Kim D.W., Kim T.B., Shin H.K., et al. A case of methimazole-induced acute hepatic failure in a patient with chronic hepatitis B carrier. Korean J Intern Med 1990, 5:69-73.
144. Schmidt G., Borsch G., Muller K.M., Wegener M. Methimazole-associated cholestatic liver injury: case report and brief literature review. Hepatogastroenterology 1986, 33:244-246.
145. Marazuela M., Sanchez de Paco G., Jimenez I., Carraro R., Fernandez-Herrera J., Pajares J.M., et al. Acute pancreatitis, hepatic cholestasis, and erythema nodosum induced by carbimazole treatment for Graves' disease. Endocr J 2002, 49:315-318.
146. Mizutani T., Murakami M., Shirai M., Tanaka M., Nakanishi K. Metabolism-dependent hepatotoxicity of methimazole in mice depleted of glutathione. J Appl Toxicol 1999, 19:193-198.
147. Mizutani T., Yoshida K., Murakami M., Shirai M., Kawazoe S. Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: structure-toxicity and metabolic studies. Chem Res Toxicol 2000, 13:170-176.
148. Williams K.V., Nayak S., Becker D., Reyes J., Burmeister L.A. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned?. J Clin Endocrinol Metab 1997, 82:1727-1733.
149. Jonas M.M., Eidson M.S. Propylthiouracil hepatotoxicity: two pediatric cases and review of the literature. J Pediatr Gastroenterol Nutr 1988, 7:776-779.
150. Ichiki Y., Akahoshi M., Yamashita N., Morita C., Maruyama T., Horiuchi T., et al. Propylthiouracil-induced severe hepatitis: a case report and review of the literature. J Gastroenterol 1998, 33:747-750.
151. Ruiz J.K., Rossi G.V., Vallejos H.A., Brenet R.W., Lopez I.B., Escribano A.A. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003, 37:224-228.
152. Kim H.J., Kim B.H., Han Y.S., Yang I., Kim K.J., Dong S.H., et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 2001, 96:165-169.
153. Russo M.W., Galanko J.A., Shrestha R., Fried M.W., Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004, 10:1018-1023.
154. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009, 15:719-729.
155. Hayashida C.Y., Duarte A.J., Sato A.E., Yamashiro-Kanashiro E.H. Neonatal hepatitis and lymphocyte sensitization by placental transfer of propylthiouracil. J Endocrinol Invest 1990, 13:937-941.
156. Testa G., Trevino J., Bogetti D., Layden T., Wiley T., Sankary H., et al. Liver transplantation for propylthiouracil-induced acute hepatic failure. Dig Dis Sci 2003, 48:190-191.
157. Carrion A.F., Czul F., Arosemena L.R., Selvaggi G., Garcia M.T., Tekin A., et al. Propylthiouracil-induced acute liver failure: role of liver transplantation. Int J Endocrinol 2010, 2010:910636.
158. Aydemir S., Ustundag Y., Bayraktaroglu T., Tekin I.O., Peksoy I., Unal A.U. Fulminant hepatic failure associated with propylthiouracil: a case report with treatment emphasis on the use of plasmapheresis. J Clin Apher 2005, 20:235-238.
159. Primeggia J., Lewis J.H. Gone (from the Physicians' Desk Reference) but not forgotten: propylthiouracil-associated hepatic failure: a call for liver test monitoring. J Natl Med Assoc 2010, 102:531-534.
160. Rivkees S.A., Mattison D.R. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009, 2009:132041.